Search

Displaying results 1871 - 1880 of 9314 in total
  1. Drug

    Fencamfamin

    go.drugbank.com/drugs/DB01463
    ApprovedIllicitWithdrawn

    It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. … It is especially useful in patients with chronic conditions due to its favourable safety profile.

  2. Drug

    Eszopiclone

    go.drugbank.com/drugs/DB00402
    ApprovedInvestigational

    It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_. … Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia.

  3. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.

  4. Drug

    Ertugliflozin

    go.drugbank.com/drugs/DB11827
    ApprovedInvestigational

    Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. … [A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621]

  5. Drug

    Emapalumab

    go.drugbank.com/drugs/DB14724
    ApprovedInvestigational

    [L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845] … [A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.

  6. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    in the context of resistant cancers. … Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing

  7. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares. … [A252220, A252225] Spesolimab received recommendations from the EMA's Committee for Medicinal Products for Human Use (CHMP) to be granted marketing authorization in October 2022 and was finally approved

  8. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  9. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    by the U.S. … By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body's ability to mineralize bone, thereby preventing serious skeletal and

  10. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma. … Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.

    Synonyms: IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN CD3E (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN)), HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE WITH IMMUNOGLOBULINCategories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager